Platelet apoptosis and agonist-mediated activation in myelodysplastic syndromes

Summary

Patients with myelodysplastic syndromes (MDS) have a defect in the differentiation of bone marrow multipotent progenitor cells. Thrombocytopenia in MDS patients may be due to premature megakaryocyte death, but platelet apoptotic mechanisms may also occur. This study aimed to study function and apoptotic state of platelets from MDS patients with different platelet count. Reticulated platelets, platelet activation, activated caspases and annexin-V binding were evaluated by flow cytometry. Pro-apoptotic Bax and Bak proteins were determined by western blots and plasma thrombopoietin by ELISA. Microparticle-associated procoagulant activity and thrombin generation capacity of plasma were determined by an activity kit and calibrated automated thrombography, respectively. High plasma thrombopoietin levels and low immature circulating platelet count showed a pattern of hypoplastic thrombocytopenia in MDS patients. Platelets from MDS patients showed reduced activation capacity and more apoptosis signs than controls. Patients with the lowest platelet count showed less platelet activation and the highest extent of platelet apoptosis. On this basis, patients with thrombocytopenia should suffer more haemorrhagic episodes than is actually observed. Consequently, we tested whether there were some compensatory mechanisms to counteract their expected bleeding tendency. Microparticle-associated procoagulant activity was enhanced in MDS patients with thrombocytopenia, whereas their plasma thrombin generation capacity was similar to control group. This research shows a hypoplastic thrombocytopenia that platelets from MDS patients possess an impaired ability to be stimulated and more apoptosis markers than those from healthy controls, indicating that MDS is a stem cell disorder, and then, both number and function of progeny cells, might be affected.

Keywords

Platelet pathology - myelodysplastic syndromes - GP IIb/IIIa activation - platelet apoptosis

^* MM and RdP contributed equally to this work.

• References

• 1 Aul C, Giagounidis A, Germing U. Epidemiological features of myelodysplastic syndromes: results from regional cancer surveys and hospital-based statistics. Int J Hematol 2001; 73: 405-410.
• 2 Greenberg PL, Young NS, Gattermann N. Myelodysplastic syndromes. Hematology Am Soc Hematol Educ Program 2002; 136-161.
• 3 Bennett JM, Catovsky D, Daniel MT. et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982; 51: 189-199.
• 4 Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002; 100: 2292-2302.
• 5 Greenberg P, Cox C, LeBeau MM. et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079-2088.
• 6 Gonzalez-Porras JR, Cordoba I, Such E. et al. Prognostic Impact of Severe Thrombocytopenia in Low-Risk Myelodysplastic Syndrome. Cancer 2011; 117: 5529-5537.
• 7 Houwerzijl EJ, Blom NR, van der Want JJL. et al. Increased peripheral platelet destruction and caspase-3-independent programmed cell death of bone marrow megakaryocytes in myelodysplastic patients. Blood 2005; 105: 3472-3479.
• 8 Kile BT. The role of the intrinsic apoptosis pathway in platelet life and death. J Thromb Haemost 2009; 07 (Suppl. 01) 214-217.
• 9 Hayashi S, Oshida M, Kiyoi T. et al. Reticulated platelet determination: methodologies and applications for the evaluation of thrombocytopenic disorders. Rinsho Ketsueki 1999; 40: 205-212.
• 10 Hemker HC, Giesen PLA, Ramjee M. et al. Thrombogram: Monitoring Thrombin Generation in Platelet Rich Plasma. Thromb Haemost 2000; 83: 589-591.
• 11 Ichikawa N, Ishida F, Shimodaira S. et al. Regulation of serum thrombopoietin levels by platelets and megakaryocytes in patients with aplastic anemia and idiopathic thrombocytopenic purpura. Thromb Haemost 1996; 76: 156-160.
• 12 Emmons RV, Reid DM, Cohen RL. et al. Human thrombopoietin levels are high when thrombocytopenia is due to megakaryocyte deficiency and low when due to increased platelet destruction. Blood 1996; 87: 4068-4071.
• 13 Kienast J, Schmitz G. Flow cytometric analysis of thiazole orange uptake by platelets: a diagnostic aid in the evaluation of thrombocytopenic disorders. Blood 1990; 75: 116-121.
• 14 Bowles KM, Warner BA, Baglin TP. Platelet mass has prognostic value in patients with myelodysplastic syndromes. Br J Haematol 2006; 135: 198-200.
• 15 Germing U, Platzbecker U, Giagounidis A. et al. Platelet morphology, platelet mass, platelet count and prognosis in patients with myelodysplastic syndromes. Br J Haematol 2007; 138: 396-403.
• 16 Girtovitis FI, Ntaios G, Papadopoulos A. et al. Defective Platelet Aggregation in Myelodysplastic Syndromes. Acta Haematol 2007; 118: 117-122.
• 17 Raman BK, Van Slyck EJ, Riddle J. et al. Platelet function and structure in myeloproliferative disease, myelodysplastic syndrome, and secondary thrombocytosis. Am J Clin Pathol 1989; 91: 647-655.
• 18 Sandes AF, Yamamoto M, Matarraz S. et al. Altered immunophenotypic features of peripheral blood platelets in myelodysplastic syndromes. Haematologica 2012; 97: 895-902.
• 19 Podrez EA, Byzova TV, Febbraio M. et al. Platelet CD36 links hyperlipidemia, oxidant stress and a prothrombotic phenotype. Nat Med 2007; 13: 1086-1095.
• 20 Kuter DJ, Beeler DL, Rosenberg RD. The purification of megapoietin: a physiological regulator of megakaryocyte growth and platelet production. Proc Natl Acad Sci USA 1994; 91: 11104-11108.
• 21 Kaushansky K. Thrombopoietin: the primary regulator of platelet production. Blood 1995; 86: 419-431.
• 22 Tamura H, Ogata K, Luo S. et al. Plasma thrombopoietin (TPO) levels and expression of TPO receptor on platelets in patients with myelodysplastic syndromes. Br J Haematol 1998; 103: 778-784.
• 23 Cesari F, Marcucci R, Caporale R. et al. Relationship between high platelet turnover and platelet function in high-risk patients with coronary artery disease on dual antiplatelet therapy. Thromb Haemost 2008; 99: 930-935.
• 24 Monteagudo M, Amengual MJ, Munoz L. et al. Reticulated platelets as a screening test to identify thrombocytopenia aetiology. QJM 2008; 101: 549-555.
• 25 Saigo K, Takenokuchi M, Imai J. et al. Usefulness of immature platelet fraction for the clinical evaluation of myelodysplastic syndromes. Lab Hematol 2009; 15: 13-16.
• 26 Kurata Y, Hayashi S, Kiyoi T. et al. Diagnostic value of tests for reticulated platelets, plasmaglycocalicin, and thrombopoietin levels for discriminating between hyperdestructive and hypoplastic thrombocytopenia. Am J Clin Pathol 2001; 115: 656-664.
• 27 Taylor RC, Cullen SP, Martin SJ. Apoptosis: controlled demolition at the cellular level. Nat Rev Mol Cell Biol 2008; 09: 231-241.
• 28 Kodama T, Takehara T, Hikita H. et al. BH3-only activator proteins Bid and Bim are dispensable for Bak/Bax-dependent thrombocyte apoptosis induced by BclxL deficiency: molecular requisites for the mitochondrial pathway to apoptosis in platelets. J Biol Chem 2011; 286: 13905-13913.
• 29 Mason KD, Carpinelli MR, Fletcher JI. et al. Programmed anuclear cell death delimits platelet life span. Cell 2007; 128: 1173-1186.
• 30 Oltersdorf T, Elmore SW, Shoemaker AR. et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005; 435: 677-681.
• 31 Wilson WH, O’Connor OA, Czuczman MS. et al. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol 2010; 11: 1149-1159.
• 32 Tse C, Shoemaker AR. et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 2008; 68: 3421-3428.
• 33 Schoenwaelder SM, Yuan Y, Josefsson EC. et al. Two distinct pathways regulate platelet phosphatidylserine exposure and procoagulant function. Blood 2009; 114: 663-666.
• 34 Schoenwaelder S, Jarman KE, Gardiner EE. et al. Bcl-xL-inhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of platelets. Blood 2011; 118: 1663-1674.
• 35 Zeidman A, Sokolover N, Fradin Z. et al. Platelet function and its clinical significance in the myelodysplastic syndromes. Hematol J 2004; 05: 234-238.
• 36 Sims PJ, Wiedmer T. Unraveling the mysteries of phospholipid scrambling. Thromb Haemost 2001; 86: 266-275.
• 37 Bevers EM, Comfurius P, Dekkers DW. et al. Lipid translocation across the plasma membrane of mammalian cells. Biochim. Biophys Acta 1999; 1439: 317-330.
• 38 Heemskerk JW, Bevers EM, Lindhout T. Platelet activation and blood coagulation. Thromb Haemost 2002; 88: 186-193.
• 39 Sims PJ, Wiedmer T, Esmon CT. et al. Assembly of the platelet prothrombinase complex is linked to vesiculation of the platelet plasma membrane. Studies in Scott syndrome: an isolated defect in platelet procoagulant activity. J Biol Chem 1989; 264: 17049-17057.
• 40 Comfurius P, Senden JM, Tilly RH. et al. Loss of membrane phospholipid asymmetry in platelets and red cells may be associated with calcium-induced shedding of plasma membrane and inhibition of aminophospholipid translocase. Biochim Biophys Acta 1990; 1026: 153-160.
• 41 Morel O, Toti F, Hugel B. et al. Cellular microparticles: a disseminated storage pool of bioactive vascular effectors. Curr Opin Hematol 2004; 11: 156-164.
• 42 Fuhler GM, Knol GJ, Drayer AL. et al. Impaired interleukin-8- and GROalpha-induced phosphorylation of extracellular signal-regulated kinase result in decreased migration of neutrophils from patients with myelodysplasia. J Leukoc Biol 2005; 77: 257-266.
• 43 Fuhler GM, Blom NR, Coffer PJ. et al. The reduced GM-CSF priming of ROS production in granulocytes from patients with myelodysplasia is associated with an impaired lipid raft formation. J Leukoc Biol 2007; 81: 449-457.
• 44 Fianchi L, Leone G, Posteraro B. et al. Impaired bactericidal and fungicidal activities of neutrophils in patients with myelodysplastic syndrome. Leuk Res 2012; 36: 331-333.
• 45 Kantarjian H, Issa J-PJ, Rosenfeld C. et al. Decitabine improves patient outcomes in myelodysplastic syndromes. Cancer 2006; 106: 1794-1803.
• 46 Fenaux P, Raza A, Mufti GJ. et al. A multicenter phase 2 study of the farnesyl-transferase inhibitor tipifarnib in intermediate- to high-risk myelodysplastic syndrome. Blood 2007; 109: 4158-4163.
• 47 List A, Kurtin S, Roe DJ. et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 2005; 352: 549-557.
• 48 Platzbecker U, Haase M, Herbst R. et al. Activity of sirolimus in patients with myelodysplastic syndrome-results of a pilot study. Br J Haematol 2005; 1285: 625-630.
• 49 Silverman LR, Demakos EP, Peterson BL. et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 2002; 20: 2429-2440.